1. A Randomized Trial of the Efficacy and Acceptability of a Pen Injector
- Author
-
D. J. O’Sullivan, E. Gayer, D. P. Murray, G. H. Tomkin, Peter Salmon, P. Keenan, and M. I. Drury
- Subjects
Adult ,Male ,medicine.medical_specialty ,Ultralente ,Injections, Subcutaneous ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Drug Administration Schedule ,law.invention ,Random Allocation ,Endocrinology ,Patient satisfaction ,Randomized controlled trial ,law ,Surveys and Questionnaires ,Diabetes mellitus ,Internal Medicine ,medicine ,Humans ,Insulin ,Syringe ,Glycated Hemoglobin ,Clinical Trials as Topic ,Insulin, Regular, Pork ,business.industry ,Insulin pen ,Consumer Behavior ,medicine.disease ,Recombinant Proteins ,Surgery ,Insulin, Long-Acting ,Regimen ,Diabetes Mellitus, Type 1 ,Anesthesia ,Female ,business - Abstract
A controlled trial of pen injection of insulin was performed in 78 patients, with assessment of metabolic control and lifestyle. After a 6-week run-in period, during which control was optimized, the patients were randomized, either to stay on a twice daily insulin regimen (n = 37), or to change to a three times daily pen regimen with human ultralente at night (n = 41). Over the 20 weeks, there was no significant change in mean glycosylated haemoglobin (syringe, mean +/- SD, 11.1 +/- 2.5% to 10.9 +/- 2.0%; pen, 11.3 +/- 2.6% to 11.2 +/- 2.0%), in blood glucose profiles or in frequency of hypoglycaemic attacks in either group. A self-completed questionnaire demonstrated high patient satisfaction with the pen injector (NovoPen), 78% for effect on lifestyle and 81% for increased flexibility. Ninety-five percent preferred the pen injector regimen to conventional treatment and stayed on it.
- Published
- 1988
- Full Text
- View/download PDF